Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children7510.24287/1726-1708-2017-16-3-92-104СтатьиDabigatran etexilate: a new oral anticoagulantДабигатран этексилат: новый антикоагулянт для перорального введенияhttps://orcid.org/0000-0002-5948-3444SinauridzeE. I.СинауридзеЕ.И.
Russian Federation

PhD, Leading Researcher, Laboratory of Biophysics

Senior Researcher, Laboratory of the Molecular Mechanisms of Hemostasis, Center for Theoretical Problems of Physicochemical Pharmacology

Russia, 117997, Moscow, Samory Mashela st., 1

https://orcid.org/0000-0003-3491-1884VuimoT. A.ВуймоТ.А.
Russian Federation

Russia, 117997, Moscow, Samory Mashela st., 1

https://orcid.org/0000-0003-3403-181XAtaullakhanovF. I.АтауллахановФ.И.
Russian Federation

Russia, 117997, Moscow, Samory Mashela st., 1

Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Center for Theoretical Problems of Physicochemical PharmacologyЦентр теоретических проблем физико-химической фармакологии РАН, МоскваФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, МоскваDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, МоскваDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Center for Theoretical Problems of Physicochemical Pharmacology Department of Physics, Moscow State UniversityЦентр теоретических проблем физико-химической фармакологии РАН, Москва, Физический факультет Московского государственного университета, МоскваФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, Москва100820171639210410082018Copyright ©; 2017, «D. Rogachev NMRCPHOI»Copyright ©; 2017, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2017«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/75

The article presents a review of the data about a new oral anticoagulant dabigatran etexilate (DE), which is the pro-drug, but in the body converts after oral administration in the active compound, a direct low-molecular weight thrombin inhibitor dabigatran. The major properties of dabigatran and DE, pharmacokinetic parameters of the preparation and its interactions with the other drugs are examined. Efficiency and safety of this preparation's clinical use in different pathological states are discussed also. The review of pharmacodynamics and the methods for measurement of the DE anticoagulant activity are  presented. The possible advantages of DE compare to other anticoagulants are discussed, also as the questions of clinical trials of DE for using in pediatric population.

В статье представлен обзор данных о новом оральном антикоагулянтном препарате дабигатран этексилате (ДЭ), который является пролекарством, но после перорального введения превращается в организме в действующее вещество - прямой низкомолекулярный ингибитор тромбина дабигатран. Представлены основные свойства дабигатрана и ДЭ, фармакокинетические параметры препарата, его взаимодействия с другими лекарственными соединениями, а также эффективность и безопасность его использования при различных патологиях. Представлен обзор фармакодинамики ДЭ и методов анализа его антикоагулянтной эффективности. Обсуждаются возможные преимущества ДЭ по сравнению с другими антикоагулянтами и вопросы клинических исследований ДЭ для применения в детской популяции.

anticoagulant therapydabigatran etexilatemonitoringnew oral anticoagulantspeculiarities of anticoagulation in pediatric populationpharmacodynamicspharmacokineticsthrombin inhibitorантикоагулянтная терапиядабигатран этексилатингибитор тромбинамониторингновые оральные антикоагулянтыособенности антикоагуляции в детской популяциифармакодинамикафармакокинетика1. Sinauridze E.I., Panteleev M.A., Ataullakhanov F.I. Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis 2012; 23 (6): 482-93.Sinauridze E.I., Panteleev M.A., Ataullakhanov F.I. Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis 2012; 23 (6): 482-93.2. Kouides P.A., Fricke W. Diagnosis and management of heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 2005; 3 (2): 335-45.Kouides P.A., Fricke W. Diagnosis and management of heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 2005; 3 (2): 335-45.3. Tadros R., Shakib S. Warfarin - indications, risks and drug interactions. Aust Fam Physician 2010; 39 (7): 476-9.Tadros R., Shakib S. Warfarin - indications, risks and drug interactions. Aust Fam Physician 2010; 39 (7): 476-9.4. Vermeer C. Vitamin K: the effect on health beyond coagulation - an overview. Food Nutr Res. 2012 Apr 2 [cited 2017 Feb 9]; 56:1, 5329 (6 p.). doi: 10.3402/fnr.v56i0.5329 Available from: http://dx.doi.org/10.3402/fnr.v56i0.5329.Vermeer C. Vitamin K: the effect on health beyond coagulation - an overview. Food Nutr Res. 2012 Apr 2 [cited 2017 Feb 9]; 56:1, 5329 (6 p.). doi: 10.3402/fnr.v56i0.5329 Available from: http://dx.doi.org/10.3402/fnr.v56i0.5329.5. Weitz J.I., Eikelboom J.W., Samama M.M. American College of Chest Physicians. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2): e120S-51S.Weitz J.I., Eikelboom J.W., Samama M.M. American College of Chest Physicians. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2): e120S-51S.6. Eriksson B.I., Quinlan D.J., Eikelboom J.W. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011; 62:41-57.Eriksson B.I., Quinlan D.J., Eikelboom J.W. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011; 62:41-57.7. Weitz J.I. Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 2007; 5 (Suppl. 1): 65-7.Weitz J.I. Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 2007; 5 (Suppl. 1): 65-7.8. Saito H., Matsushita T., Kojima T. Historical perspective and future direction of coagulation research. J Thromb Haemost 2011; 9 (Suppl. 1): 352-63.Saito H., Matsushita T., Kojima T. Historical perspective and future direction of coagulation research. J Thromb Haemost 2011; 9 (Suppl. 1): 352-63.9. Stone S.R., Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25(16): 4622-8.Stone S.R., Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25(16): 4622-8.10. Menear K. Direct thrombin inhibitors: current status and future prospects. Expert Opin Investig Drugs 1999; 8 (9): 1373-84.Menear K. Direct thrombin inhibitors: current status and future prospects. Expert Opin Investig Drugs 1999; 8 (9): 1373-84.11. Scatena R. Bivalirudin: a new generation antithrombotic drugs. Expert Opin Investig Drugs 2000; 9 (5): 1119-27.Scatena R. Bivalirudin: a new generation antithrombotic drugs. Expert Opin Investig Drugs 2000; 9 (5): 1119-27.12. Summary of product characteristics (Revasc). 2007 Jul 9 [cited 2017 Feb 9]; (about 8 p.). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000104/WC500055498.pdf; and Summary of product characteristics (Refludan). 2007 Mar 05 [cited 2017 Feb 9]; (about 19 p.) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000122/WC500049442.pdf.Summary of product characteristics (Revasc). 2007 Jul 9 [cited 2017 Feb 9]; (about 8 p.). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000104/WC500055498.pdf; and Summary of product characteristics (Refludan). 2007 Mar 05 [cited 2017 Feb 9]; (about 19 p.) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000122/WC500049442.pdf.13. Schwarz R.P. The preclinical and clinical pharmacology of Novastan (Argatroban). In: Pifarre R., editor. New Anticoagulants for the Cardiovascular Patient. Philadelphia, PA, US: Hanley and Belfus Inc.; 1997. p. 231-49.Schwarz R.P. The preclinical and clinical pharmacology of Novastan (Argatroban). In: Pifarre R., editor. New Anticoagulants for the Cardiovascular Patient. Philadelphia, PA, US: Hanley and Belfus Inc.; 1997. p. 231-49.14. Hauel N.H., Nar H., Priepke H., Ries U., Stassen J.-M., Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45 (9): 1757-66.Hauel N.H., Nar H., Priepke H., Ries U., Stassen J.-M., Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45 (9): 1757-66.15. Blech S., Ebner T., Ludwig-Schwellinger E., Stangier J., Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36 (2): 386-99.Blech S., Ebner T., Ludwig-Schwellinger E., Stangier J., Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36 (2): 386-99.16. Stangier J., Rathgen K., Stähle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64 (3): 292-303.Stangier J., Rathgen K., Stähle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64 (3): 292-303.17. Hankey G.J., Eikelboom J.W. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123 (13): 1436-50.Hankey G.J., Eikelboom J.W. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123 (13): 1436-50.18. Wienen W., Stassen J.-M., Priepke H., Ries U.J., Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98 (1): 155-62.Wienen W., Stassen J.-M., Priepke H., Ries U.J., Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98 (1): 155-62.19. Baetz B.E., Spinler S.A. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28 (11): 1354-73.Baetz B.E., Spinler S.A. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28 (11): 1354-73.20. Eisert W.G., Hauel N., Stangier J., Wienen W., Clemens A., van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30 (10): 1885-9.Eisert W.G., Hauel N., Stangier J., Wienen W., Clemens A., van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30 (10): 1885-9.21. Lee K., Ansell J.E. Direct thrombin inhibitors. Br J Clin Pharmacol 2011; 72 (4): 581-92.Lee K., Ansell J.E. Direct thrombin inhibitors. Br J Clin Pharmacol 2011; 72 (4): 581-92.22. Drug Bank: Dabigatran etexilate. (2010 May 03) [cited 2017 Feb 9]. Available from: http://www.drugbank.ca/drugs/DB06695.Drug Bank: Dabigatran etexilate. (2010 May 03) [cited 2017 Feb 9]. Available from: http://www.drugbank.ca/drugs/DB06695.23. Stangier J., Stähle H., Rathger K., Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008; 47 (1): 47-59.Stangier J., Stähle H., Rathger K., Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008; 47 (1): 47-59.24. Trocóniz I.F., Tillmann C., Liesenfeld K.H., Schäfer H.G., Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement.Trocóniz I.F., Tillmann C., Liesenfeld K.H., Schäfer H.G., Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement.